- PRXL has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $32.9 million.
- PRXL has traded 2,475 shares today.
- PRXL is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in PRXL with the Ticky from Trade-Ideas. See the FREE profile for PRXL NOW at Trade-Ideas More details on PRXL: PAREXEL International Corporation is a biopharmaceutical outsourcing services company. PRXL has a PE ratio of 25. Currently there are 5 analysts that rate Parexel International a buy, no analysts rate it a sell, and 7 rate it a hold. The average volume for Parexel International has been 454,100 shares per day over the past 30 days. Parexel International has a market cap of $3.8 billion and is part of the health care sector and health services industry. The stock has a beta of 0.50 and a short float of 7.8% with 8.28 days to cover. Shares are up 27.1% year-to-date as of the close of trading on Friday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Parexel International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Highlights from the ratings report include:
- Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 27.85% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, PRXL should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
- PAREXEL INTERNATIONAL CORP has improved earnings per share by 13.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, PAREXEL INTERNATIONAL CORP increased its bottom line by earning $2.24 versus $1.63 in the prior year. This year, the market expects an improvement in earnings ($2.75 versus $2.24).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Life Sciences Tools & Services industry. The net income increased by 8.6% when compared to the same quarter one year prior, going from $34.74 million to $37.74 million.
- The debt-to-equity ratio is somewhat low, currently at 0.63, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.48, which illustrates the ability to avoid short-term cash problems.
- Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. When compared to other companies in the Life Sciences Tools & Services industry and the overall market, PAREXEL INTERNATIONAL CORP's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
- You can view the full Parexel International Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.